Rheumatologists view CAR T-cell therapy as ‘revolutionary,’ but cost, safety temper enthusiasm
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain hesitant on whether its efficacy outweighs the possible risks, according to survey data from Spherix Global Insights. “We are standing at the threshold of major change in rheumatology,” Sawyer May, insights director of rheumatology at Spherix Global Insights, told Healio. “The survey data and clinical experience […]
New Spherix Patient Research Shows Nearly Half of Atopic Dermatitis Patients Report Major Quality-of-Life Impact Despite Expanding Treatment Options
Patient-reported data reveal substantial gaps between clinical perception and lived experience across sleep, mental health, and daily functioning EXTON, PA, January 8, 2026 – More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily functioning, […]
AZ looks to grow reach in lupus with phase 3 win for self-administered Saphnelo
The full results from AstraZeneca’s phase 3 Tulip-SC trial build on the interim results that earned the drug a European approval last month. Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive phase 3 […]
UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights
High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie’s Rinvoq continue to generate strong future interest EXTON, PA, December 17, 2025 — New research from Spherix Global Insights shows that the Hidradenitis Suppurativa treatment landscape is entering a period of accelerated change as dermatologists reassess biologic use based on real-world […]
Novo’s oral semaglutide edges out CagriSema, Lilly’s orforglipron as PCPs’ most-anticipated obesity med
Oral semaglutide, which Novo has taken to calling “Wegovy in a pill,” is expected to receive an FDA decision before the end of the year. As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights surveyed […]
Approval of Roche/Genentech’s Gazyvaro Set to Reshape the EU5 Lupus Nephritis Treatment Landscape, According to Spherix Global Insights
Strong physician readiness, high efficacy expectations, and anticipated displacement of off-label rituximab position Gazyvaro for rapid adoption across Europe EXTON, PA, December 11, 2025 — Following this week’s European Commission approval of Roche/Genentech’s Gazyvaro (obinutuzumab) for the treatment of lupus nephritis (LN), Spherix Global Insights’ latest RealTime Dynamix™: Lupus Nephritis (EU) study indicates that the […]
Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights
US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness. Exton, PA., December 9, 2025 – Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited […]
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
Spherix Global Insights’ Latest Market Dynamix™ Report Reveals Intensifying Complexity in Relapsed/Refractory Multiple Myeloma Ahead of ASH 2025 Exton, PA., December 2, 2025 – “Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there’s no clear, consistent guidance – ask five academic physicians and you’ll get five different answers. It’s frustrating trying to optimize care […]
First Look at Roche/Genentech’s Gazyva Shows Strong Early Enthusiasm in Lupus Nephritis Launch, According to Spherix Global Insights
One-month post-launch, Gazyva’s perceived degree of advance exceeds benchmarks achieved by GSK’s Benlysta and Aurinia’s Lupkynis at comparable post-launch time points. EXTON, Pa., November 19, 2025 – Spherix Global Insights has released the first wave of Launch Dynamix™: Gazyva in Lupus Nephritis, providing the earliest independent read on the commercial introduction of Gazyva® (obinutuzumab, Genentech/Roche). […]
Spherix Global Insights Reports Rapidly Evolving U.S. PNH Market as Ultomiris Prescriptions Reach Parity with Iron Supplements
New chart-audit data reveal faster referrals, more patients initiating advanced therapy before hematology consultation, and heightened disease awareness among community physicians. Exton, PA., November 19, 2025 — New data from Spherix Global Insights reveal that the U.S. market for paroxysmal nocturnal hemoglobinuria (PNH) is entering a new phase of dynamism, characterized by shifting referral patterns, rapid treatment adoption, […]